Emulation of the RECORD3 Trial Using Healthcare Claims Data

N/AActive Not RecruitingNCT07599384

Brigham and Women's Hospital149,248 enrolled

Overview

Investigators are building an empirical evidence base for real-world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real-world data analyses can be conducted with confidence and how to implement such studies.

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data, but was proxied through a statistical balancing of measured covariates through standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Study Type

OBSERVATIONAL

Enrollment

149,248

Conditions

Deep Vein Thrombosis Pulmonary Embolus

Interventions

RivaroxabanDRUG

Initiation of rivaroxaban described in electronic health records is used as the exposure.

EnoxaparinDRUG

Initiation of enoxaparin described in electronic health records is used as the reference.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 18 years of age * Scheduled to undergo elective total knee replacement Exclusion Criteria: * Pregnancy or breastfeeding * Had active bleeding or high risk of bleeding * Had contraindications for prophylaxis with enoxaparin * Drug or alcohol abuse * Concomitant use of protease inhibitors for the treatment of HIV * Had planned intermittent pneumatic compression * Had a requirement for anticoagulant therapy that could not be stopped * Substantial liver disease * Severe renal impairment (creatinine clearance \<30 ml per minute) * Concurrent use of both drugs

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Time to first occurrence of deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause at 17 days

The primary outcome is the time from 1 day after prescription fill of the exposure or comparator to the first occurrence of any component of the composite endpoint: deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 17 days after elective total knee arthroplasty, comparing rivaroxaban versus enoxaparin.

Time frame: From 1 day after fill until earliest of outcome occurrence, end of data or study period, death, treatment discontinuation +10-day grace/risk window, nursing home admission, treatment augmentation, switch to other NOAC/Warfarin, assessed up to 17 days.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.